Several other markers have also been associated with poor prognosis in NSCLC (EGFR, CMET, E-cadherin, pAKT (Takanami et al, 1996; Bremnes et al, 2002; David et al, 2004; Deeb et al, 2004; Masuya et al, 2004a)), but at present there is no single marker that can be used to guide therapy or predict prognosis of NSCLC patients. This evidence concerns the gene CDH1 and non-small cell lung carcinoma.